Site search

Clear filter
2890 results for '' found
A multicentre, randomised, double-blind, placebo-controlled, dose escalation and dose finding phase II study to evaluate the safety and efficacy of IPN10200 in the prevention of episodic or chron
/
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure Wi
/
First In Human Feasibility Clinical Study Evaluating the Safety of the XPD System for Periosteal Distraction [PD] (ACTRN12625000159459)
/
A Phase 1b/2 Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP-104GI in Adults with Eosinophilic Esophagitis [RESOLVE] (NCT05608681)
/
Assessing cognitive trajectories in Progressive Supranuclear Palsy using remote computerized reaction time tasks (Trial Not Registered)
/
Memorandum for sponsors December 2025 pdf
Memo_for_sponsors_re_transition_to_Bayside_Health_151225.pdf
Alfred Health - Emergency and Trauma Centre (Easy Read) PDF
https://app.prompt.org.au/download/258119?code=759b5178-7c15-474c-bb1b-45cefbed2828
Alfred Health GP News - December 2025 pdf
Alfred_Health_GP_News_-_December_2025.pdf
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC (NCT06881784)
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC (NCT06881784)
/
A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa [BRIGHTE
A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa [BRIGHTE
/
7 8 9 10 11